Publications by authors named "D Velasco Olmos"
Article Synopsis
- - Tumor immune microenvironment (TIME) significantly influences how prostate cancer (PC) responds to treatments and understanding mechanisms of resistance is crucial.
- - Research indicates that certain genomic changes, like microsatellite instability (MSI) and CDK12 bi-allelic loss, may increase response rates to immune therapies, but patient responses vary widely.
- - The review explores how immune cell interactions within tumors affect PC progression, how standard therapies impact immune responses, and the challenges in analyzing the immune landscape related to tumors.
Solution blow spinning (SBS) is a versatile and cost-effective technique for producing nanofibrous materials. It is based on the principles of other spinning methods as electrospinning (ES), which creates very thin and fine fibers with controlled morphologies. Polylactic acid (PLA), a biodegradable and biocompatible polymer derived from renewable resources, is widely used in biomedical fields, environmental protection, and packaging.
View Article and Find Full Text PDFIntroduction: In 2017, we launched the "B-Team" (buprenorphine team), the first hospitalist-led opioid use disorder (OUD) treatment program in Texas. Based on initial success, we obtained funding from Texas Health & Human Services to expand the model to other hospitals in Texas through the Support Hospital Opioid Use Disorder Treatment (SHOUT) Texas program.
Methods: This is a mixed methods study of the implementation of the SHOUT program, which is an OUD treatment intervention, in different hospitals in Texas.
Despite novel therapeutic strategies, advanced-stage prostate cancer (PCa) remains highly lethal, pointing out the urgent need for effective therapeutic strategies. While dysregulation of the splicing process is considered a cancer hallmark, the role of certain splicing factors remains unknown in PCa. This study focuses on characterizing the levels and role of SRSF6 in this disease.
View Article and Find Full Text PDFBackground And Objective: The phase 3 MAGNITUDE trial assessed the efficacy and safety of niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in homologous recombination repair (HRR) genes. Here we report final analysis results for patient-reported outcomes (PROs) in the HRR cohort with a focus on BRCA1/2 alterations (BRCA).
Methods: Protocol-specified endpoints evaluated patient-reported symptoms, health-related quality of life (HRQoL), and tolerability (side-effect bother) using the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and EQ-5D-5L questionnaires.